{"entity":{"id":"yamamoto-noboru","kind":"person","name":"Noboru Yamamoto","aka":[],"tldr":"Runs Japan's largest first-in-human oncology unit, where many Daiichi Sankyo DXd ADCs were first given to patients.","summary":"Noboru Yamamoto is Director of the Department of Experimental Therapeutics at the National Cancer Center Hospital in Tokyo. He runs Japan's largest first-in-human oncology unit, where many of the Daiichi Sankyo DXd antibody-drug conjugates were first given to patients, including trastuzumab deruxtecan and datopotamab deruxtecan. His publications include the TROPION-PanTumor01 first-in-human study of datopotamab deruxtecan in non-small-cell lung cancer, the REMORA phase 2 trial of lenvatinib in advanced thymic carcinoma, and a phase 1 study of the anti-CCR4 antibody mogamulizumab combined with nivolumab in solid tumours. His interests are phase 1 trials, drug development and lung cancer.","asOf":"2026-09-08","links":[{"label":"National Cancer Center Hospital","url":"https://www.ncc.go.jp/en/ncch/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yamamoto%20N%5BAuthor%5D%20National%20Cancer%20Center%20phase%201"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":["trastuzumab-deruxtecan","datopotamab-deruxtecan"],"companies":["daiichi-sankyo"],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Experimental Therapeutics, National Cancer Center Hospital","institutionId":"ncc-japan","specialisms":["Phase 1 trials","Drug development","Lung cancer","Antibody-drug conjugates"],"profiles":[{"label":"National Cancer Center Hospital","url":"https://www.ncc.go.jp/en/ncch/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yamamoto%20N%5BAuthor%5D%20National%20Cancer%20Center%20phase%201"}],"papers":[{"title":"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/jco.23.00059"},{"title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","journal":"The Lancet Oncology","year":2020,"doi":"10.1016/s1470-2045(20)30162-5"},{"title":"A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors","journal":"Clinical Cancer Research","year":2019,"doi":"10.1158/1078-0432.ccr-19-1090"}]},"route":"/people/yamamoto-noboru/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}],"institution":[{"id":"ncc-japan","kind":"institution","name":"National Cancer Center Hospital","route":"/institutions/ncc-japan/"}]}}